CRIS Current Research Information System

LEMOLI, ROBERTO MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.688
AS - Asia 3.593
EU - Europa 3.400
SA - Sud America 242
AF - Africa 238
Continente sconosciuto - Info sul continente non disponibili 18
OC - Oceania 8
Totale 13.187
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.639
SG - Singapore 1.163
CN - Cina 1.022
GB - Regno Unito 870
VN - Vietnam 633
SE - Svezia 561
DE - Germania 428
IT - Italia 422
HK - Hong Kong 272
IN - India 211
UA - Ucraina 177
BR - Brasile 174
RU - Federazione Russa 172
FR - Francia 151
IE - Irlanda 147
NL - Olanda 126
ZA - Sudafrica 78
TG - Togo 69
JO - Giordania 63
FI - Finlandia 62
KR - Corea 60
JP - Giappone 58
BG - Bulgaria 57
EE - Estonia 56
CH - Svizzera 54
CI - Costa d'Avorio 48
BE - Belgio 35
CA - Canada 35
AR - Argentina 26
IR - Iran 23
SC - Seychelles 23
ES - Italia 17
EU - Europa 17
ID - Indonesia 17
PL - Polonia 17
TR - Turchia 15
MY - Malesia 14
AT - Austria 13
MX - Messico 12
PY - Paraguay 11
BD - Bangladesh 10
EC - Ecuador 9
GR - Grecia 9
AU - Australia 8
NG - Nigeria 8
CL - Cile 7
CO - Colombia 7
CZ - Repubblica Ceca 7
LB - Libano 6
PE - Perù 5
TH - Thailandia 4
TW - Taiwan 4
AZ - Azerbaigian 3
EG - Egitto 3
IQ - Iraq 3
MA - Marocco 3
HR - Croazia 2
HU - Ungheria 2
IL - Israele 2
IS - Islanda 2
KG - Kirghizistan 2
KW - Kuwait 2
KZ - Kazakistan 2
LT - Lituania 2
PT - Portogallo 2
RO - Romania 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BO - Bolivia 1
CM - Camerun 1
ET - Etiopia 1
GD - Grenada 1
GI - Gibilterra 1
JM - Giamaica 1
LI - Liechtenstein 1
MD - Moldavia 1
MK - Macedonia 1
MM - Myanmar 1
MU - Mauritius 1
NO - Norvegia 1
PH - Filippine 1
QA - Qatar 1
RS - Serbia 1
SI - Slovenia 1
SR - Suriname 1
UY - Uruguay 1
YT - Mayotte 1
Totale 13.187
Salva come PNG Salva come JPEG
Città #
Singapore 773
Southend 752
Ashburn 658
Fairfield 640
Chandler 531
Houston 451
Woodbridge 302
Hong Kong 267
Seattle 262
Wilmington 240
Ann Arbor 236
Santa Clara 207
Cambridge 201
Princeton 190
Beijing 169
Hefei 164
Dublin 147
Ho Chi Minh City 142
Dong Ket 134
Boardman 118
Hanoi 107
Jacksonville 106
Westminster 75
Los Angeles 72
Nanjing 72
Lomé 69
Padova 68
New York 66
Amman 63
Bologna 61
Seoul 60
Sofia 54
Tokyo 54
Helsinki 49
Abidjan 48
Bern 45
Bremen 45
Buffalo 45
Jinan 44
Berlin 43
San Diego 42
Shenyang 40
Dallas 38
Brussels 35
Saint Petersburg 34
Hyderabad 32
Milan 32
Tianjin 29
Turin 28
Guangzhou 27
Munich 27
Redmond 27
Redondo Beach 26
Jiaxing 22
Frankfurt am Main 21
Mülheim 21
Hebei 20
São Paulo 19
Zhengzhou 19
Changsha 18
Nanchang 18
Florence 17
Norwalk 17
Biên Hòa 15
Chicago 15
London 15
Shanghai 15
Toronto 15
Dearborn 13
Haiphong 13
Mahé 13
Medford 13
Kuala Lumpur 12
Phoenix 12
Taiyuan 12
Brooklyn 11
Ha Long 11
Quận Bình Thạnh 11
Bengaluru 10
Boston 10
Falls Church 10
Ningbo 10
Des Moines 9
Hangzhou 9
Leawood 9
Rome 9
Verona 9
Warsaw 9
Yubileyny 9
Abeokuta 8
Amsterdam 8
Da Nang 8
Haikou 8
Hải Dương 8
Johannesburg 8
Redwood City 8
San Francisco 8
Bexley 7
Bắc Giang 7
Changchun 7
Totale 8.823
Salva come PNG Salva come JPEG
Nome #
Impaired dendritic cell immunophenotype and function in heart transplant patients undergoing active cytomegalovirus infection. 355
Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis 284
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 244
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 239
CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1 226
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 218
A novel model of CCl4-induced cirrosi with ascites in the mouse. 207
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 206
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 197
NUCLEOFECTION IS AN EFFICIENT NON-VIRAL TRANSFECTION TECHNIQUE FOR HUMAN BONE MARROW-DERIVED MESENCHYMAL STEM CELLS. 196
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. 190
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 190
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 187
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 186
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. 184
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 179
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 177
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 174
Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. 172
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. 171
BU/melphalan and auto-SCT in AML patients in first CR: a 'Gruppo Italiano Trapianto di Midollo Osseo (GITMO)' retrospective study. 169
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 165
Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells 164
The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System 164
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. 161
Extracellular ATP exerts opposite effects on activated and regulatory CD4 + T cells via purinergic P2 receptor activation 159
Dendritic cell differentiation. 158
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 158
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients 158
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 157
Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells 156
Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA. 154
PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response 153
The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling 152
Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function 151
Molecular and functional characterization of CD133+stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 151
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. 150
Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. 150
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. 149
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. 147
Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. 147
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 147
Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients. 145
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 145
Stem cell mobilization and collection in patients with liver cirrhosis. 144
The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling 144
Extracellular purines promote the differentiation of human bone marrow-derived mesenchymal stem cells to the osteogenic and adipogenic lineages. 141
Platelet lysate enhances the therapeutic activity of Adipose Derived Mesenchymal stromal cells isolated from Crohn disease patients in a novel Mouse model of Colitis 138
CD 133+ stem cells for the treatment of end stage liver disease. 137
Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. 137
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 133
Gpr171, a putative P2Y-like receptor, negatively regulates myeloid differentiation in murine hematopoietic progenitors. 133
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. 132
Indoleamine 2,3-Dioxygenase (IDO) Is Associated with High Incidence of Chemorefractory Disease in Acute Myeloid Leukemia (AML) Patients 132
Hematopoietic stem cell mobilization. 131
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. 130
European Data on Stem Cell Mobilization with Plerixafor in Non-Hodgkin’s Lymphoma, Hodgkin’s Lymphoma and Multiple Myeloma Patients. A Subgroup Analysis of the European Consortium of Stem Cell Mobilization. 129
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 129
The kinetic status of hematopoietic stem cell subpopulations underlies a differential expression of genes involved in self-renewal, commitment, and engrftment. 127
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 124
The Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) Regulates the Function and Migration of Leukemic Blasts through CD63/PI3K/AKT/P21 Axis 123
Stem cell plasticity: time for a reappraisal ? 121
Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging 119
Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. 119
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 119
INFLAMMATORY PATHWAYS IN THE BONE MARROW: ROLE OF TIMP-1 IN HEMATOPOIETIC STEM/PROGENITOR CELLS AND LEUKEMIA 118
More ADO about IDO: GVHD. 118
Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product 113
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 110
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV 106
Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. 104
The CD47 pathway is deregulated in human immune thrombocytopenia 103
INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia 102
Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. 100
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. 100
The sixth sense: Hematopoietic Stem Cells detect danger through purinergic signalling. 99
Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo italianoTrapianto di Midollo Osseo. 98
null 97
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 96
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy 94
New strategies for stem cell mobilization 93
CD133+ hematopoietic stem cells reinfusion in end-stage liver disease (ESLD): final results of a phase I clinical trial 86
The P2X7 receptor: a new player in IL-1 processing and release 85
Zoledronic acid modulates function and differentiation of myeloid cells. 84
Pre-emptive use of Plerixafor in hard-to-mobilize patients: An emerging concept. 83
Granulocyte colony-stimulating factor promotes the generation of regulatory DCs through induction of IL-10 and IFN-alfa. 81
Pegfilgrastim for mobilization of stem cells in allogeneic donors. 81
Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia 75
Reinfusion of highly purified CD133+ stem cells in patients with end-stage liver disease (ESLD): final results of a phase I clinical trial 68
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 66
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 66
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome 63
Erratum: Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients (Haematologica (2005) 90, (225-231). 54
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation 47
Evaluation of immunotoxins containing single-chain ribosome- inactivating proteins and an anti-CD22 monoclonal antibody (OM124): In vitro and in vivo studies 40
Immunotoxins containing recombinant anti-CTLA-4 single-chain fragment variable antibodies and saporin: In vitro results and in vivo effects in an acute rejection model 38
Ber‐H2 (anti‐CD30)‐saporin immunotoxin: a new tool for the the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation 35
In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins 33
European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization. 15
Mobilization with chemotherapy+G-CSF+Plerixafor in Europe: The Italian experience. 2
Totale 13.387
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.922
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.922
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021618 0 0 0 0 0 57 12 64 109 74 55 247
2021/20221.777 135 79 103 180 141 100 48 123 54 163 339 312
2022/20232.020 257 289 107 266 120 166 65 92 348 52 138 120
2023/2024545 45 79 42 77 58 130 34 22 7 21 12 18
2024/20251.946 85 306 163 210 327 98 98 49 20 167 75 348
2025/20262.590 517 513 412 387 544 217 0 0 0 0 0 0
Totale 13.387